FDA Approved Natpara, the First Biologic to Treat a Rare Disease, Hypoparathyroidism

NPS Pharmaceutical, Inc., headquartered in Bedminster, New Jersey, USA, won FDA approval on January 23, 2015 for Natpara, the first bioengineered replacement therapy cleared for U.S. marketing to treat hypoparathyroidism.  FDA...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Life Science Leaders Celebrate Global Partnerships During WuXi Global Forum 2018

More than 2,000 life science industry insiders around the globe participated in the WuXi Global Forum on Jan. 9, 2018 during the annual J.P....

WuXi Global Forum 2018